Phase II Study of Bevacizumab and Docetaxel (AvaTax) in Metastatic Esophagogastric Cancer
Bevacizumab will be administered intravenously in an outpatient clinic once a week, every
other week. Docetaxel will also be administered intravenously in the outpatient clinic once
a week for three out of four weeks. Blood tests and vital signs will be performed weekly.
After the first eight weeks of therapy a CT scan will be performed to determine and assess
the progress of the disease. If therapy is continued, radiological procedures will be
performed at week 16 and every 8 weeks thereafter.
Treatment will be given for a minimum of 8 weeks, as long as the patient does not experience
unacceptable side effects. Chemotherapy will continue for a year and a half as long as the
cancer is responding and there are no unacceptable side effects.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the overall response and safety of the combination docetaxel and bevacizumab in patients with esophageal or gastric cancer
Peter Enzinger, MD
Dana-Farber Cancer Institute
United States: Food and Drug Administration
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|